Vimian Group AB

Research Vimian Group AB (VIMIAN) on Bullrun: market cap SEK 18.77B, P/E 46.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 18.77B; P/E is 46.2.

Peer valuation comparison

Latest P/E is 46.17x versus a Healthcare sector median of 24.46x (88.8% above).

Latest P/E is 46.17x versus a Sweden median of 18.57x (148.6% above).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-28SEK 18.77B46.2n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Vimian Group AB's market cap?

Vimian Group AB's market capitalization is SEK 18.77B.

What is Vimian Group AB's P/E ratio?

Vimian Group AB's price-to-earnings (P/E) ratio is 46.2.

What does Vimian Group AB do?

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.